US 11,834,391 B2
Pantothenamide analogues
Josephus Schalkwijk, CK Molenhoek (NL); Pedro Harold Han Hermkens, KZ Oss (NL); Koen Jakob Dechering, XW Nijmegen (NL); and Roger Victor Bonnert, Loughborough (GB)
Assigned to MMV MEDICINES FOR MALARIA VENTURE, Geneva (CH)
Filed by MMV MEDICINES FOR MALARIA VENTURE, Geneva (CH)
Filed on Jan. 20, 2023, as Appl. No. 18/099,279.
Application 18/099,279 is a division of application No. 17/418,871, granted, now 11,572,336, previously published as PCT/EP2019/087147, filed on Dec. 30, 2019.
Claims priority of application No. 18215980 (EP), filed on Dec. 31, 2018.
Prior Publication US 2023/0159437 A1, May 25, 2023
Int. Cl. C07C 235/10 (2006.01); A61P 33/06 (2006.01); A61K 45/06 (2006.01); C07C 255/60 (2006.01)
CPC C07C 235/10 (2013.01) [A61K 45/06 (2013.01); A61P 33/06 (2018.01); C07C 255/60 (2013.01)] 15 Claims
 
1. A method for preventing and/or treating a protozoan infection in a subject, said method comprising administering a compound selected from the group consisting of the pantothenamide analogues represented by formula (I):

OG Complex Work Unit Chemistry
wherein ring E represents an optionally substituted phenyl ring or a pharmaceutically acceptable salt thereof, said protozoan infection being caused by a protozoan species of one of the following genera: Plasmodium, Trypanosoma, Giardia, Cryptosporidium, Amoeba, Toxoplasma, Trichomonas or Leishmania.